As­traZeneca's di­a­betes drug grant­ed fast track des­ig­na­tion for heart fail­ure; Ver­ri­ca sends skin in­fec­tion treat­ment to FDA

→ A cou­ple weeks af­ter an­nounc­ing that their di­a­betes drug cut the risk of CV death or wors­en­ing of heart fail­ure by 26% in a land­mark study, As­traZeneca an­nounced that the FDA has grant­ed fast track des­ig­na­tion for Farx­i­ga in adults with heart fail­ure with re­duced ejec­tion frac­tion (HFrEF) or pre­served ejec­tion frac­tion (HF­pEF). The drug was giv­en the same des­ig­na­tion last month for re­nal fail­ure and the pre­ven­tion of re­nal death and CV in pa­tients with chron­ic kid­ney dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER